Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G.

Mol Cancer Ther. 2011 Jan;10(1):90-103. doi: 10.1158/1535-7163.MCT-10-0688.

2.

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.

Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM.

Free Radic Biol Med. 2012 Jan 15;52(2):377-91. doi: 10.1016/j.freeradbiomed.2011.10.487. Epub 2011 Nov 3.

PMID:
22094224
3.

Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.

Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, Zhang Z, Li C, Li Y.

Oncotarget. 2015 Oct 20;6(32):32930-43. doi: 10.18632/oncotarget.5405.

4.

Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.

Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers CM, Simonds GR, Gourdie RG, Sheng Z.

Cancer Res. 2016 Jan 1;76(1):139-49. doi: 10.1158/0008-5472.CAN-15-1286. Epub 2015 Nov 5.

5.

Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.

Golden EB, Cho HY, Jahanian A, Hofman FM, Louie SG, Schönthal AH, Chen TC.

Neurosurg Focus. 2014 Dec;37(6):E12. doi: 10.3171/2014.9.FOCUS14504.

PMID:
25434381
6.

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.

Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, Ng WH, Lai SH, Ho MM, Dinesh N, Tham CK, Lam PY.

BMC Cancer. 2015 Apr 11;15:255. doi: 10.1186/s12885-015-1191-3.

7.

The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells.

Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, Hong YK, Joe YA.

Cancer Lett. 2015 May 1;360(2):195-204. doi: 10.1016/j.canlet.2015.02.012. Epub 2015 Feb 11.

PMID:
25681668
8.

Targeting autophagy to sensitive glioma to temozolomide treatment.

Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z.

J Exp Clin Cancer Res. 2016 Feb 2;35:23. doi: 10.1186/s13046-016-0303-5. Review.

9.

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH.

Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.

10.

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Banelli B, Carra E, Barbieri F, Würth R, Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi D, Florio T, Daga A, Romani M.

Cell Cycle. 2015;14(21):3418-29. doi: 10.1080/15384101.2015.1090063.

11.

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.

Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.

12.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
13.

Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.

Liu XY, Zhang L, Wu J, Zhou L, Ren YJ, Yang WQ, Ming ZJ, Chen B, Wang J, Zhang Y, Yang JM.

PLoS One. 2013 Nov 26;8(11):e81345. doi: 10.1371/journal.pone.0081345. eCollection 2013.

14.

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.

Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, Rodriguez-Aguirre M, Ibañez CE, Kasahara N, Gunzburg W, Gruber HE, Pertschuk D, Jolly DJ, Robbins JM.

Cancer Gene Ther. 2013 Oct;20(10):544-51. doi: 10.1038/cgt.2013.51. Epub 2013 Aug 23.

PMID:
23969884
15.

Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.

Gilbert CA, Daou MC, Moser RP, Ross AH.

Cancer Res. 2010 Sep 1;70(17):6870-9. doi: 10.1158/0008-5472.CAN-10-1378. Epub 2010 Aug 24.

16.

SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.

Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.

Oncotarget. 2014 Oct 30;5(20):9703-9.

17.

Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.

Lan F, Pan Q, Yu H, Yue X.

J Neurochem. 2015 Sep;134(5):811-8. doi: 10.1111/jnc.13174. Epub 2015 Jun 11.

18.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

19.

Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J.

Cancer Sci. 2014 May;105(5):583-91. doi: 10.1111/cas.12397. Epub 2014 Apr 19.

20.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

Supplemental Content

Support Center